Rabies Vaccine Market Research, 2032
The global rabies vaccine market size was valued at $1.2 billion in 2022, and is projected to reach $1.9 billion by 2032, growing at a CAGR of 4.7% from 2023 to 2032. Rabies vaccine market growth is majorly driven by high presence of market players who manufactures rabies vaccine, availability of high-quality rabies vaccines for prevention of rabies, and technological advancements for development of rabies vaccine. Increase in prevalence of rabies is anticipated to drive the growth of rabies vaccine market. For instance, according to the World Health Organization, in September 2023, it was reported that rabies is estimated to cause 59 000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia. The burden of disease is disproportionally borne by rural poor populations, with approximately half of cases attributable to children under 15 years of age.
Key Takeaways:
- By product type, the chick embryo cells rabies vaccine segment dominated the rabies vaccine market share in 2022.
- By prophylaxis type, the post exposure prophylaxis segment dominated the rabies vaccine market share in 2022.
- By application, human segment dominated the market in 2022.
- By end user, the hospitals segment dominated the market in 2022.
- By region, North America dominated the market in 2022 and is expected to grow during the forecast period.
Rabies is a deadly viral disease that affects mammals, including humans. The virus is primarily transmitted through the saliva of infected animals, typically via bites or scratches. The rabies virus is usually transmitted to humans through the bite of an infected animal. However, it can also be transmitted if infected saliva comes into contact with mucous membranes (such as the eyes, nose, or mouth) or open wounds.
A rabies vaccination, often simply referred to as a rabies shot, is a preventive medical treatment that involves the administration of a vaccine to protect individuals and animals from the rabies virus. Rabies vaccinations are given to individuals and animals before or after potential exposure to the rabies virus to prevent the onset of the disease. There are two primary forms of rabies vaccination which includes pre-exposure prophylaxis and post exposure prophylaxis.
Market Dynamics
Rise in the prevalence of dog bite is anticipated to boost the demand for rabies vaccine and expected to witness growth of rabies vaccine market during the forecast period. For instance, according to the World Health Organization, in September 2023, every year, more than 29 million people worldwide receive rabies post-exposure prophylaxis (PEP). This is estimated to prevent hundreds of thousands of rabies deaths annually. Globally, the economic burden of dog-mediated rabies is estimated at $8.6 billion per year.
Moreover, rise in initiatives taken by government and private organization is expected to boost the growth rabies vaccine market. For instance, in India, in the month of March 2023, according to Ministry of Fisheries, Animal Husbandry & Dairying, The Central Government launched the National Rabies Control Program (NRCP) for prevention and control of Rabies. The stray dog population control and management of stray dogs is the mandate of the local bodies. The central government has framed the animal birth control (Dogs) Rules, 2023 which is to be implemented by the local authority to control the population of stray dogs. The main focus of the rules is on anti-rabies vaccination of stray dogs and neutering of stray dogs as means of population stabilization.
In addition, rise in initiative by government for dog vaccination is anticipated to boost the growth of market. For instance, in September 2021, according to National Library of Medicine, it was reported that, China revised the Animal Epidemic Prevention Law of the People’s Republic of China in 2021, which stipulates the requirement for dog owners to vaccinate dogs against rabies and perform civilized dog breeding. This law provides a national legal guarantee for the elimination of dog-mediated human rabies in China.
On the other hand, the factor that is anticipated to hamper the growth of market includes the lack of awareness about rabies, its risks, and the importance of vaccination. This can lead to lower demand for vaccines and less investment in preventive measures. In addition, less prevalence of rabies in developed countries such as U.S., Canada, U.K and others is expected to hinder the growth of market in forecast period. For instance, according to Center for Disease Control and prevention, cases of human rabies cases in the U.S. are rare, with only 1 to 3 cases reported annually. Twenty-five cases of human rabies have been reported in the U.S. in the past decade (2009-2018). Seven of these infections were acquired outside of the U.S. and its territories.
Segmental Overview
The rabies vaccine market size is segmented on the basis of product type, prophylaxis type, application, end user, and region. By product type the market is divided into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. By prophylaxis type, the market is classified into pre-exposure prophylaxis and post exposure prophylaxis. By application, the market is segmented into human and animal. By end user, the market is categorized into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
By Product Type
The market is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine and others. Others includes human diploid cell vaccine (HDCV) and baby hamster kidney (BHK) cells rabies vaccine. The chick embryo cells rabies vaccine segment is expected to be the fastest growing segment during the forecast period owing to rise in prevalence of rabies in developing countries and increase in awareness among the people regarding importance of vaccination.
By Prophylaxis Type
The market is classified into pre-exposure prophylaxis and post exposure prophylaxis. The post exposure prophylaxis segment is projected to be the fastest growing segment during the forecast period owing to rise in number of dog bite which is anticipated to cause rabies and increase in number of populations get expose to bite or scratch of animal suffering from rabies.
By Application
The market is segmented into human and animal. The human segment is projected to be the fastest growing segment during the forecast period owing to rise in number of pre and post exposure prophylaxis in human and increase in awareness among the population regarding vaccination.
By End User
The market is classified into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics. The hospital segment is projected to be the fastest growing segment during the forecast period owing to increase in prevalence of rabies and rise in the number of people taking rabies vaccination in hospitals.
By Region
The North America rabies vaccine market opportunity is expected to grow during the forecast period, owing to presence of large market players such as Zoetis, Elanco, Merck & Co., Inc., and others who manufactures high quality rabies vaccines for animals. In addition, increase expenditure of U.S. government on rabies vaccination and high awareness among the people regarding importance of vaccination is expected to fuel the growth of market during the forecast period. For instance, according to Animal and Plant Health Inspection Service, a U.S. department of Agriculture, it was reported that, rabies is a serious public health concern because if left untreated it is always fatal. Costs associated with detection, prevention, and control of rabies exceed $300 million annually. According to the Centers for Disease Control and Prevention, about 90% of reported rabies cases in the U.S. are in wildlife.
In addition, according to Center for Disease Control and prevention, each year hundreds of thousands of animals need to be placed under observation or be tested for rabies, and between 30,000 to 60,000 people need to receive rabies postexposure prophylaxis. Thus, rise in number of postexposure prophylaxis rabies vaccination among people, presence of large market players and increase in expenditure for rabies vaccination is expected to boost the growth of rabies vaccine industry in the forecast period.
However, the rabies vaccine market forecast is expected to grow, owing to rise in number of populations suffering from rabies. For instance, according to report of Ministry of Health and Family Welfare Government of India, in 2022, an estimated 35172 human deaths (59.6% of global deaths) and loss of approximately 2.2 million disability adjusted life years (DALYs) occur per year in Asia due to dog-mediated rabies. India accounts for the most deaths in Asia (65% of human rabies deaths) and globally (36% of human rabies deaths). The cost of PEP is highest in Asia, with estimates up to US$ 1.5 billion per year.
Competition Analysis
Some of the major companies that operate in the rabies vaccine industry include Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA.
Recent Collaboration in the Rabies Vaccine Market
In August 2022, Boehringer Ingelheim International GmbH, a pharmaceutical company, announced collaboration with NGOs and Global Alliance of Rabies Control to set up mass vaccination program for the dogs.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2022 to 2032 to identify the prevailing rabies vaccine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.
Rabies Vaccine Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 1.9 billion |
 Growth Rate | CAGR of 4.7% |
 Forecast period | 2022 - 2032 |
 Report Pages | 451 |
 By Product Type |
|
 By Prophylaxis Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Elanco Animal Health Incorporated., Merck & Co., Inc., Sanofi, Virbac SA, Cadila Pharmaceuticals Ltd, Boehringer Ingelheim International GmbH, Zoetis Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Novartis AG |
Analyst Review
The rabies virus infects the central nervous system. Symptoms occur from days to years after exposure to the virus and include delirium (confusion), abnormal behavior, hallucinations, hydrophobia (fear of water), and insomnia (difficulty sleeping), which precede coma and death. Rabies vaccine prevents rabies if given to a person after an exposure.
Increase in adoption of key strategies such as product launch and rise in initiatives taken by government are anticipated to boost the growth of market. For instance, in April 2022, Cadila Pharmaceuticals, a pharmaceutical company, launched the world’s first novel three-dose rabies vaccine ThRabis. ThRabis is prepared by using Virus-Like Particle technology (VLP). The VLPs self-assemble from this recombinant G protein, which is produced from genes cloned into baculovirus expression vectors and expressed in Spodoptera frugiperda (Sf9) insect cells. The vaccine generates antibodies against rabies G protein, which leads to virus neutralization, as well as prevents virus attachment to the cell to confer protection against rabies.
In addition, rise in number of clinical trials for rabies vaccine is anticipated to boost the growth of market. For instance, in June 2023, YS Biopharma, a pharmaceutical company, dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announced that its PIKA rabies vaccine was granted Phase 3 clinical trial approval from the Food and Drug Administration of the Philippines.
The top companies that hold the market share in rabies vaccine market are Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., and Virbac SA.
North America is anticipated to witness lucrative growth during the forecast period, owing to high presence of market players.
The key trends in the rabies vaccine market are large presence of rabies vaccine manufacturers and rise in number of populations suffering from rabies and increase in awareness among the population regarding importance of vaccination.
The base year for the report is 2022.
10 rabies vaccine companies are profiled in the report.
The total market value of rabies vaccine market is $1,207.03 million in 2022.
The forecast period in the report is from 2023 to 2032.
High cost of rabies vaccine is restraining factor for rabies vaccine market.
Loading Table Of Content...
Loading Research Methodology...
